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Elevated serum ferritin is associated with reduced survival following allogeneic transplantation and an in-
creased risk of toxic and infectious complications after autologous hematopoietic stem cell transplantation
(ASCT). We studied 315 patients who underwent ASCT for Hodgkin (HL) or non-Hodgkin lymphoma
(NHL) at our institution in whom pretransplantation ferritin was available to determine its association
with survival. On multivariate analysis, a pretransplantation ferritin .685 ng/mL was associated with signif-
icantly lower overall (OS; P5 .002) and relapse-free survival (RFS; P5 .021). Ferritin.685 ng/mL was asso-
ciated with a higher incidence of relapse (P 5 .005) and relapse mortality (P\.001), but not of nonrelapse
mortality (NRM; P5 .23). Similar results were seen when pretransplantation ferritin was analyzed as a con-
tinuous variable and by quartiles. Our results indicate the need for studies designed to correlate an elevated
ferritin with iron overload and to analyze the benefit of strategies to reduce the extent of iron overload.
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Iron overload is an adverse prognostic factor for
patients undergoing allogeneic stem cell transplanta-
tion for thalassemia [1,2]. Elevated levels of serum
ferritin, the most widely used surrogate for iron
stores, are associated with worse outcomes following
transplantation for acute leukemia and myelodys-
plastic syndrome (MDS) [3] and are also associated
with an increased risk of organ toxicity following
autologous stem cell transplantation (ASCT) [4,5].
The aim of this study was to determine the relation-
ship between pretransplantation ferritin levels and
outcome following ASCT for Hodgkin and non-
Hodgkin lymphoma.
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Patients
The records of 375 consecutive adult patients who
underwent ASCT for Hodgkin (HL) and non-Hodg-
kin lymphoma (NHL) at the Cleveland Clinic between
November 2000 andDecember 2006 were reviewed. A
pretransplantation serum ferritin (drawn within 100
days preceding transplant admission) was available
for 315 patients (86%) who form the patient popula-
tion for this report.
Institutional review board approval was obtained
to perform this study in accordance with the Declara-
tion of Helsinki.
Peripheral Blood StemCell (PBSC)Mobilization
and Autologous Transplantation
Twohundred sixty-four patients received etoposide
2 g/m2 with granulotyce-colony stimulating factor
(G-CSF) 10mg/kg/day subcutaneously formobilization
of stem cells, 35 patients underwent mobilization with
G-CSF alone, 13 patients with G-CSF with AMD-
3100, and 3 patients withG-CSF and other chemother-
apy agents. Aminimumdose of 2.0 106 CD341 cells/
kg was required to proceed with transplantation.1239
1240 Biol Blood Marrow Transplant 14:1239-1244, 2008A. Mahindra et al.Figure 1. Outcome of patients stratified by pretransplantation ferritin level. Patients are stratified using recursive partitioning analysis. (A) overall sur-
vival. (B) relapse mortality. (C) non relapse mortality.Three hundred twelve patients received a prepara-
tive regimen of oral busulfan (Bu) 14 mg/kg, etoposide
60 mg/kg, and cyclophosphamide (Cy) 120 mg/kg.
Three patients received Bu 16 mg/kg and Cy 120
mg/kg.
Patients were hospitalized for administration of
the preparative regimen and were routinely discharged
after hematologic recovery.
Statistical Analysis
Recursive partitioning analysis (RPA) with a
log-rank splitting method was used to identify the
cut off point in baseline ferritin that best correlated
with overall survival (OS) among the 315 study pa-
tients, regardless of other study variables. This cut
off point was used in the analysis of all outcomes, as
were ferritin as a continuous variable, and ferritin
quartiles. The association of pretransplantation char-
acteristics with elevated ferritin was assessed using
the chi-square test (categoric variables) or Wilcoxon
test (continuous variables). Outcomes were estimated
using the Kaplan-Meyer method and compared be-
tween patients with and without elevated ferritin usingthe log-rank test. Outcomes included OS, relapse-free
survival (RFS), relapse, relapse mortality, and nonre-
lapse mortality (NRM).
Cox proportional hazards analysis was used to
identify univariable and multivariable risk factors for
relapse, OS, and RFS. Because the focus of this study
was to assess the prognostic effect of ferritin after ad-
justing for other study variables, each multivariable
Cox model included ferritin and any factor prognostic
for the outcome at P\ .10. Each of these variables was
retained in the multivariable model regardless of its
statistical significance or lack thereof. The factors as-
sessed include age at transplant, sex, primary diagnosis,
months from diagnosis to transplantation, number of
prior chemotherapy regimens, prior radiation therapy,
ferritin, albumin, bilirubin, aspartate transaminase
(AST), alkaline phosphatase, lactate dehydrogenase
(LDH) pretransplantation, disease status at transplant,
preparative regimen, and CD341 dose. Because most
of the patients in the analysis were referred from and
returned to outside practices after transplant, an accu-
rate history of the number of red blood cell transfu-
sions prior to or following transplantation was not
possible.
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Ferritin #685 ng/mL (185) Ferritin >685 ng/mL (130)
N (%) N (%) P-value
Median age at transplant, years (range) 51(19-77) 55(23-75) .011
Sex, male 106(57) 94(72) .006
Diagnosis
Non-Hodgkin lymphoma 146(79) 111(85) .14
Hodgkin lymphoma 39(21) 19(15)
Median interval from diagnosis to transplant, months (range) 16(2-233) 19(4-372) .19
<9 months 50(27) 27(21) .58
9-18 months 50(27) 36(28)
18-44 months 45(24) 33(25)
>44 months 40(22) 34(26)
Prior radiation therapy 56(31) 33(26) .36
Courses of chemotherapy
1 54(30) 12(9) <.001
2 89(49) 66(52)
3 28(15) 35(27)
4-12 12(7) 15(12)
Albumin <4.0 36(20) 31(25) .29
Bilirubin #1ULN 182(100) 123(99) .22
AST #2ULN 180(99) 123(99) .80
Alkaline phosphatase >1ULN 32(18) 51(41) <.001
LDH >1ULN 114(62) 80(63) .85
Disease status at transplant
Complete remission 1 13(7) 7(5) .72
Complete remission 2+ 34(19) 19(15)
Partial remission 121(66) 91(71)
Relapsed 15(8) 12(9)
Preparative regimen
Bu/Cy/VP-16 183(99) 129(99) .78
Bu/Cy 2(1) 1(1)
CD34+ dose, 106/kg 8.98(2.01-65.18) 7.15(2.04-42.75) <.001
AST indicates aspartate transaminase; LDH, lactate dehydrogenase; ULN, upper limit of normal.Results of Cox proportional hazards analyses are
summarized as the hazard ratio (HR) and 95% confi-
dence interval (CI) for the hazard ratio. P\ .05 was
used to indicate statistical significance for all analyses.
Analyses were performed using SAS software (SAS
Institute Inc., Cary, NC).
RESULTS
The survival of the 315 study patients did not differ
significantly from that of the 60 patients without an
available baseline ferritin (P 5 .26).
The normal range for ferritin in our laboratory is
18 to 300 ng/mL. The median pretransplantation fer-
ritin for patients in this study was 577 ng/mL (range:
12.8-4115). RPA identified a baseline ferritin .685
ng/mL as the cut off point that best correlated with
poor survival (Figure 1A); 130 patients (41%) had
a pretransplantation ferritin .685 ng/mL. The clini-
cal characteristics of the 130 patients with a pretrans-
plantation ferritin .685 ng/mL are compared with
those of the 185 patients with a pretransplantation
ferritin #685 ng/mL in Table 1. The number of
courses of chemotherapy received prior to transplant
was significantly higher (P \ .001) in patients with
a pretransplantation ferritin .685 ng/mL. The me-dian follow-up for surviving patients is 18.2 months
(range: 1.2-75.4).
Univariable analysis demonstrated that age, num-
ber of prior chemotherapy regimens, low albumin, el-
evated alkaline phosphatase, and elevated ferritin were
significantly associated with OS. The univariable anal-
ysis of prognostic factors assessed for influence on OS,
RFS, and relapse is summarized in Table 2.
Multivariable analysis demonstrated that elevated
ferritin (P 5 .002, HR 2.02, 95% CI 1.29-3.16) and
low albumin (P 5 .025, HR 1.67, 95% CI 1.07-
2.60) were significant adverse prognostic factors for
OS. Elevated ferritin (P 5 .021, HR 1.60, 95% CI
1.08-2.38) and low albumin (P 5 .008, HR 1.70,
95% CI 1.15-2.51) were also adverse factors for
RFS (Table 3).
Ferritin. 685 ng/mL was associated with a higher
incidence of relapse (P5 .005) and relapse mortality (P
\ .001; Figure 1B), but not of NRM (P 5 .23;
Figure 1C).
When pretransplantation ferritin was analyzed as
a continuous variable, it was significantly associated
with OS (P 5 .008, HR 1.01, 95% CI 1.01-1.06),
RFS (P 5 .006, HR 1.03, 95% CI 1.01-1.06), relapse
(P 5 .008, HR 1.04, 95% CI 1.01-1.06), and relapse
mortality (P \ .001, HR 1.05, 95% CI 1.02-1.08),
but not with NRM (P 5 .65, HR 1.01, 95% CI
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Overall Survival Relapse-Free Survival Relapse
Variable HR 95%CI P HR 95%CI P HR 95%CI P
Age at transplant, per 10-year increase 1.19 1.01-1.40 .034 1.08 0.94-1.24 .29 1.02 0.87-1.18 0.84
Male sex 1.19 0.78-1.83 .42 1.13 0.78-1.64 .51 1.34 0.87-2.05 0.18
Primary diagnosis HL/NHL 0.99 0.59-1.66 .98 1.08 0.69-1.68 .74 1.08 0.66-1.79 0.75
Months from diagnosis to transplant, per 6
month increase
1.00 0.98-1.03 .7 0.99 0.97-1.02 .63 0.98 0.95-1.01 0.20
9.01-18/<9 1.46 0.84-2.56 .18 1.23 0.77-1.98 .39 1.23 0.73-2.07 0.44
18.01-44/<9 0.89 0.47-1.71 .73 0.84 0.49-1.43 .52 0.85 0.48-1.52 0.59
>44/<9 1.32 0.73-2.37 .36 0.99 0.60-1.65 .98 0.80 0.44-1.43 0.45
Number of prior chemotherapy regimens, per 1
regimen increase
1.24 1.04-1.47 .016 1.16 1.00-1.34 .047 1.16 0.99-1.37 0.07
Prior radiation therapy 1.28 0.84-1.97 .25 1.02 0.69-1.50 .93 0.90 0.58-1.41 0.65
Disease status at transplant
CR2+/CR1 1.53 0.44-5.39 .50 1.70 0.58-5.03 .34 2.30 0.51-10.26 0.28
PR/CR1 1.86 0.58-5.91 .30 2.08 0.76-5.69 .15 3.40 0.83-13.86 0.09
Relapsed/CR1 2.71 0.74-9.86 .13 3.50 1.15-10.6 .028 6.54 1.48-29.04 0.014
CD34+ dose, per 5 x 106/kg increase 0.89 0.77-1.03 .12 0.89 0.79-1.01 .06 0.90 0.79-1.03 0.14
Bu/Cy/VP preparative regimen 0.71 0.10-5.12 .74 1.05 0.15-7.50 .96 0.83 0.12-5.96 0.85
LDH >1xULN 1.38 0.90-2.12 .14 1.16 0.80-1.68 .43 1.20 0.79-1.83 0.38
Bilirubin, per 0.1 unit increase 1.02 0.92-1.14 .66 0.99 0.90-1.10 .91 0.97 0.86-1.09 0.60
Alkaline phosphatase > 1xULN 2.22 1.45-3.38 <.001 1.93 1.33-2.80 <.001 1.59 1.03-2.45 0.036
Aspartate transaminases, 2xULN 0.76 0.10-5.42 .78 0.64 0.09-4.56 .65 0.83 0.12-5.98 0.86
Albumin <4.0 1.88 1.22-2.90 .004 2.00 1.37-2.92 <.001 1.93 1.26-2.96 0.002
Ferritin >685 2.35 1.56-3.53 <.001 1.80 1.26-2.56 .001 1.76 1.18-2.62 0.005
HR indicates hazard ratio; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CR, complete remission; ULN, upper limit of
normal.0.96-1.07). In addition, we examined pretransplanta-
tion ferritin in quartiles and found a linear association
of ferritin with OS (Figure 2A) and relapse mortality
(Figure 2B) but not NRM (Figure 2C).
DISCUSSION
Elevated pretransplantation ferritin levels are
associated with increased mortality and worse trans-
plant-related survival following allogeneic hematopoi-
etic stem cell transplantation. Because of its predictive
value, the pretransplant ferritin level has been incorpo-
rated into a prognostic scoring system for patients un-
dergoing myeloablative allogeneic transplantation for
acute leukemia and MDS [6].
This study demonstrates an association between
elevated ferritin levels and OS and RFS following
ASCT for lymphoma. Although the association of ele-
vated ferritin with outcome is presumed to relate to its
correlation with increased iron stores, ferritin may be
elevated in other circumstances, including inflamma-
tion. Notably, the inclusion of albumin in the multi-
variate model, as a negative acute phase reactant [3],
did not alter the impact of ferritin on outcome. Eryth-
rocyte sedimentation rate or C-reactive protein (CRP)
values, markers of acute inflammation, were not rou-
tinely performed, and hence were not included in the
analysis. Elevated ferritin may also occur in association
with abnormal liver function tests and greater extent ofmalignancy, but these parameters were accounted for
in multivariate analysis.
Free iron can lead to oxygen-derived free radical-
mediated tissue injury [7]. In patients undergoing
bone marrow transplantation serum iron and ferritin
rise 2 to 3 days prior to bone marrow infusion [8],
and nontransferrin bound serum iron appears shortly
after the start of conditioning and remains detectable
in most patients throughout the peritransplantation
period [9]. Previous studies have postulated that iron
overload may increase susceptibility to organ damage
and risk of infections [10-12]. Yet this study demon-
strates no significant increase in NRM in patients
with elevated ferritin levels. Improved supportive
care, particularly management of infectious complica-
tions following autologous transplantation, may have
overcome any potential adverse impact on NRM. In
addition, even though our study cohort is large, the
incidence of NRM is low and a statistically significant
difference would be difficult to detect.
Unexpectedly, the adverse influence of elevated
ferritin occurs predominantly through its association
with relapse and relapse mortality. Iron plays a critical
role in cell proliferation; tumor cells require more iron
for DNA synthesis than normal cells probably related
to their rapid proliferation [13]. Decreased tumor
growth has been observed in iron-deficient mice [14].
Furthermore, iron chelators inhibit tumor cell growth
in vitro [15]. Thus, accumulating data suggests that el-
evated iron stores, apart from providing amilieu for in-
fection and organ toxicity and hence increased risk for
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our demonstration of an association of ferritin level
with relapse and relapse mortality will add to the impe-
tus for further study. It is an intriguing finding, but re-
quires prospective validation.
It is important to recognize the limitations of this
study. Ferritin is used here and in other reports as an
indicator of iron overload, but its correlation with
iron overload is imprecise. Ferritin may be a surrogate
for more advanced disease and thus have an impact on
Table 3. Prognostic Factors: Multivariable Analysis
Variable HR 95% CI P
Multivariable model for overall survival
Ferritin >685 ng/mL 2.02 1.29-3.16 .002
Albumin <4 g/dL 1.67 1.07-2.60 .025
Multivariable model for relapse-free survival
Ferritin >685 ng/mL 1.60 1.08-2.38 .021
Albumin <4 g/dL 1.70 1.15-2.51 .008
Multivariable model for relapse
Ferritin >685 ng/mL 1.51 0.97-2.40 .049
Albumin <4 g/dL 1.64 1.06-2.55 .026
Relapsed disease at time of transplant 4.78 1.06-21.64 .042
HR indicates hazard ratio; CI, confidence interval.relapse. As in other studies [16], the incorporation of
disease status at the time of transplantation and inter-
val from diagnosis to transplantation in multivariate
analysis does not exclude a potential effect of the ma-
lignancy on ferritin levels. Studies of some nonhema-
tologic malignancies suggest an adverse prognostic
impact of elevated ferritin even after adjustment for tu-
mor and patient characteristics [17,18]. The present
study cannot distinguish between a causal relationship
of elevated ferritin, through iron stores, on the malig-
nancy and ferritin being a surrogate for extent or
aggressiveness of malignancy.
Magnetic resonance imaging (MRI) assessment of
iron overload in the heart and liver of hematopoietic
stem cell transplant recipients reveals correlation of
hepatic T2* abnormalities with abnormal ferritin
levels [19]. A recent study reporting the prevalence of
iron overload following allogeneic transplantation in-
dicates that, although serum ferritin is a good screen-
ing test, the liver iron concentration using R2 MRI
correlates only moderately with serum ferritin [20].
It will be important to prospectively estimate the prev-
alence of clinically significant iron overload in patientsFigure 2. Outcome of patients stratified by pretransplantation ferritin level. Patients are stratified using quartiles. (A) overall survival. (B) relapse mor-
tality. (C) non relapse mortality.
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cific MRI and to analyze the correlation with serum
ferritin levels [19-21]. This approach might provide
insight into the mechanisms by which elevated ferritin
influences transplant outcome and would better deter-
mine whether patients might benefit from interven-
tions to reduce iron overload.
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